Nivolumab or Nivolumab + Ipilimumab vs Ipilimumab in advanced melanoma

• Research type

  Research Study

• Full title

  A Phase 3, Randomized, Double-Blind Study of Nivolumab Monotherapy or Nivolumab Combined with Ipilimumab Versus Ipilimumab Monotherapy in Subjects with Previously Untreated Unresectable or Metastatic Melanoma. (CheckMate 067: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 067)

• IRAS ID

  127704

• Contact name

  James Larkin

• Contact email

  James.larkin@rmh.nhs.uk

• Sponsor organisation

  Bristol Myers Squibb International Corporation

• Eudract number

  2012-005371-13

• ISRCTN Number

  n/a

• Clinicaltrials.gov Identifier

  n/a

• REC name

  South Central - Berkshire Research Ethics Committee

• REC reference

  13/SC/0264

• Date of REC Opinion

  3 Jun 2013

• REC opinion

  Favourable Opinion